Losigamone

Source: Wikipedia, the free encyclopedia.
Losigamone
Skeletal formula of losigamone
Ball-and-stick model of the losigamone molecule
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • (2R)-2-[(S)-(2-chlorophenyl)-hydroxymethyl]-3-methoxy-2H-furan-5-one
JSmol)
  • Clc1ccccc1C(O)C2OC(=O)C=C2OC
  • InChI=1S/C12H11ClO4/c1-16-9-6-10(14)17-12(9)11(15)7-4-2-3-5-8(7)13/h2-6,11-12,15H,1H3/t11-,12-/m0/s1 ☒N
  • Key:ICDNYWJQGWNLFP-RYUDHWBXSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Losigamone (

partial seizures.[1] Phase III clinical trials were conducted around the year 2000.[2]

Mechanism of action

The mechanism of action is not known. Data regarding the interaction of losigamone with

hippocampal slices.[2] Interaction with potassium[2] and sodium channels[3] has been proposed. Results from both in vitro and in vivo experiments confirm that the pharmacological activity profiles of the two losigamone enantiomers are not identical and suggest further that excitatory amino acid-mediated processes are involved in the mode of action of (+)-losigamone (the compound shown in the image) whereas (–)-losigamone does not possess such properties.[4]

References

  1. S2CID 25270336
    .
  2. ^
    PMID 11892943
    .
  3. PMID 9163572
    .
  4. PMID 10578135
    .
Stub icon

This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Losigamone&oldid=1154587905"